Press Releases

MacDougall Creative 11/27/23 MacDougall Creative 11/27/23

OncoNano Medicine Announces First Patient Dosed in Phase 1 Study Evaluating ONM-501 in Patients with Advanced Solid Tumors and Lymphomas

MacDougall Creative 11/6/23 MacDougall Creative 11/6/23

OncoNano Medicine Announces Promotion of Kartik Krishnan, MD, PhD, to President and Head of Research & Development

MacDougall Creative 11/3/23 MacDougall Creative 11/3/23

OncoNano Medicine Announces Positive Preclinical Data for ON-BOARD™ IL-12 Program at SITC 2023 Annual Meeting

MacDougall Creative 10/17/23 MacDougall Creative 10/17/23

OncoNano Medicine to Present Preclinical Data for ON-BOARD™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

MacDougall Creative 9/6/23 MacDougall Creative 9/6/23

OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in ONM-501 Study

MacDougall Creative 5/31/23 MacDougall Creative 5/31/23

OncoNano Medicine Presents Positive Final Results from Phase 2 Trial of Pegsitacianine in Podium Presentation at 2023 ASCO Annual Meeting

MacDougall Creative 4/27/23 MacDougall Creative 4/27/23

OncoNano Medicine Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

MacDougall Creative 4/18/23 MacDougall Creative 4/18/23

OncoNano Presents Compelling Data for ONM-501 and a Novel Tumor Specific Delivery Technology at AACR Annual Meeting 2023

MacDougall Creative 3/27/23 MacDougall Creative 3/27/23

OncoNano Medicine Presents Data from Phase 2 Pegsitacianine Study at Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care

MacDougall Creative 3/16/23 MacDougall Creative 3/16/23

OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2023

MacDougall Creative 1/4/23 MacDougall Creative 1/4/23

OncoNano Medicine’s Pegsitacianine Granted Breakthrough Therapy Designation for Real-Time Surgical Imaging by the Food and Drug Administration